TScan Therapeutics, Inc. cash flow to debt ratio of -143.75% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

TScan Therapeutics, Inc.'s free cash flow has decreased 21.87% from $-114.65M last year to $-139.73M, signaling decreasing performance

TScan Therapeutics, Inc.'s debt to equity ratio is 0.95, which means that the company's assets are unhealthy financed, signaling financial risk. READ MORE: A ratio over 0.60 means the company finances its assets with debt, signaling financial risk. If ratio is negative, the company spent its own equity and risks bankruptcy

TScan Therapeutics, Inc.'s debt has increased relative to shareholder equity from 0.40 last year to 0.95 today, signaling weakened financials

TScan Therapeutics, Inc. has negative EBITDA, making leverage ratio unreliable

TScan Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

TScan Therapeutics, Inc.'s profit margin has increased (-69.95%) in the last year from -4.53K% to -1.36K%, signaling increasing performance

TScan Therapeutics, Inc.'s short-term assets of $157.21M exceed its short-term liabilities of $18.70M

TScan Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

TScan Therapeutics, Inc.'s return on equity of -91.94%, is lower than 15.00%, indicating bad performance

TScan Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

TScan Therapeutics, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

TScan Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

TScan Therapeutics, Inc. has negative free cash flow, indicating cash burn

TScan Therapeutics, Inc.'s yearly earnings has decreased 1.78% since last year from $-127.50M to $-129.77M, signaling decreasing performance

TScan Therapeutics, Inc.'s yearly revenue has increased 266.65% since last year from $2.82M to $10.32M, signaling increasing performance

ROIC -67.93% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

TScan Therapeutics, Inc.'s 3-year revenue CAGR of -8.63% is negative, indicating declining revenue over the past 3 years

TScan Therapeutics, Inc. had revenue growth in 4.00 out of 5 years, indicating consistent revenue performance

TScan Therapeutics, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

TScan Therapeutics, Inc. has insufficient data to evaluate this check.

TScan Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

TScan Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

TScan Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

TScan Therapeutics, Inc. has insufficient data to evaluate this check.

TScan Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

TScan Therapeutics, Inc. has a price-to-book ratio of 1.30x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

TScan Therapeutics, Inc. has a price-to-sales ratio of 6.48x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue